Integra Lifesciences Holdings (IART) Capital Expenditures (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Capital Expenditures data on file, last reported at $14.8 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 48.66% year-over-year to $14.8 million; the trailing twelve-month figure through Mar 2026 stood at $67.4 million (down 42.85% YoY), and the FY2025 full-year result was $81.4 million, down 22.01% from the prior year.
• Capital Expenditures eased to $14.8 million in Q1 2026, from $17.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $29.7 million in Q2 2024 to a low of $9.2 million in Q3 2022.
• A 5-year average of $18.2 million and a median of $15.5 million in 2024 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 126.69% in 2024 and sank 48.88% in 2025, its largest moves.
• Tracing IART's Capital Expenditures over 5 years: stood at $14.5 million in 2022, then surged by 69.72% to $24.5 million in 2023, then increased by 20.64% to $29.6 million in 2024, then slumped by 41.84% to $17.2 million in 2025, then declined by 13.74% to $14.8 million in 2026.
• Business Quant data shows IART's Capital Expenditures at $14.8 million in Q1 2026, $17.2 million in Q4 2025, and $15.2 million in Q3 2025.